Dogwood Therapeutics, Inc.
DWTX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.01 | -0.00 | -0.00 |
| FCF Yield | -22.14% | -58.55% | -64.84% | -187.91% |
| EV / EBITDA | -0.31 | 1.62 | -14.85 | -0.53 |
| Quality | ||||
| ROIC | -17.67% | -4.14% | -4.69% | -8.27% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.21 | 1.06 | 0.43 | 0.79 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 18.71% | 14.02% | 23.63% | -573.69% |
| Safety | ||||
| Net Debt / EBITDA | 0.63 | 3.38 | -13.21 | -0.10 |
| Interest Coverage | 0.00 | 0.00 | -30.12 | -48.52 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |